Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 9, p. 868, doi. 10.1111/dom.12675

By:

• Allas, S.;
• Delale, T.;
• Ngo, N.;
• Julien, M.;
• Sahakian, P.;
• Ritter, J.;
• Abribat, T.;
• van der Lely, A. J.

Publication type:

Article